MacroGenics, Inc.
Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

Last updated:

Abstract:

CD 19.times.CD3 bi-specific monovalent diabodies, and particularly, CD 19.times.CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.

Status:
Grant
Type:

Utility

Filling date:

22 Sep 2015

Issue date:

28 Apr 2020